The landscape of castration-resistant prostate carcinoma has changed completely in the last few years, with the approval of four new agents with proven benefit in overall survival. Abiraterone, cabazitaxel, enzalutamide and radium-223 dichloride have been added to the armamentarium of available agents for the treatment of these patients. We still lack information about which agent works best in an individual patient and how to optimally use them in a sequential strategy. Cabozantinib, a targeted agent against MET and vascular endothelial growth factor receptor-2, has shown promising results and could become the first targeted therapy to be approved for castration-resistant prostate carcinoma. This paper reviews the clinical development of cabozantinib in prostate cancer and future research possibilities for this drug.
Written by:
Pinto A. Are you the author?
Medical Oncology Department, University Hospital La Paz-IdiPAZ, Madrid, Spain.
Reference: Cancer Chemother Pharmacol. 2013 Nov 8. Epub ahead of print.
doi: 10.1007/s00280-013-2343-2
PubMed Abstract
PMID: 24202668
UroToday.com mCRPC Treatment Section
